These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 35460969)
41. Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. Welge V; Fiege O; Lewczuk P; Mollenhauer B; Esselmann H; Klafki HW; Wolf S; Trenkwalder C; Otto M; Kornhuber J; Wiltfang J; Bibl M J Neural Transm (Vienna); 2009 Feb; 116(2):203-12. PubMed ID: 19142572 [TBL] [Abstract][Full Text] [Related]
42. Surface plasmon resonance biosensors for detection of Alzheimer's biomarkers; an effective step in early and accurate diagnosis. Rezabakhsh A; Rahbarghazi R; Fathi F Biosens Bioelectron; 2020 Nov; 167():112511. PubMed ID: 32858422 [TBL] [Abstract][Full Text] [Related]
43. Diagnosis of Alzheimer's disease utilizing amyloid and tau as fluid biomarkers. Lee JC; Kim SJ; Hong S; Kim Y Exp Mol Med; 2019 May; 51(5):1-10. PubMed ID: 31073121 [TBL] [Abstract][Full Text] [Related]
44. The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease. Engelborghs S; Le Bastard N Mol Diagn Ther; 2012 Jun; 16(3):135-41. PubMed ID: 22646065 [TBL] [Abstract][Full Text] [Related]
45. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease. Li X; Li TQ; Andreasen N; Wiberg MK; Westman E; Wahlund LO J Intern Med; 2014 Apr; 275(4):418-27. PubMed ID: 24237038 [TBL] [Abstract][Full Text] [Related]
46. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease. Leuzy A; Carter SF; Chiotis K; Almkvist O; Wall A; Nordberg A J Alzheimers Dis; 2015; 45(4):1077-88. PubMed ID: 25649653 [TBL] [Abstract][Full Text] [Related]
47. Precise profiling of exosomal biomarkers via programmable curved plasmonic nanoarchitecture-based biosensor for clinical diagnosis of Alzheimer's disease. Song S; Lee JU; Jeon MJ; Kim S; Lee CN; Sim SJ Biosens Bioelectron; 2023 Jun; 230():115269. PubMed ID: 37001292 [TBL] [Abstract][Full Text] [Related]
48. Molecular approaches to the treatment, prophylaxis, and diagnosis of Alzheimer's disease: clinical molecular and genetic studies on Alzheimer's disease. Shoji M J Pharmacol Sci; 2012; 118(3):345-9. PubMed ID: 22382661 [TBL] [Abstract][Full Text] [Related]
49. Impact of the 2008-2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study. Gabelle A; Dumurgier J; Vercruysse O; Paquet C; Bombois S; Laplanche JL; Peoc'h K; Schraen S; Buée L; Pasquier F; Hugon J; Touchon J; Lehmann S J Alzheimers Dis; 2013; 34(1):297-305. PubMed ID: 23186986 [TBL] [Abstract][Full Text] [Related]
50. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes. Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545 [TBL] [Abstract][Full Text] [Related]
51. Alzheimer's Disease Biomarker Detection Using Field Effect Transistor-Based Biosensor. Le PG; Choi SH; Cho S Biosensors (Basel); 2023 Nov; 13(11):. PubMed ID: 37998162 [TBL] [Abstract][Full Text] [Related]
52. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model. Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W; J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262 [TBL] [Abstract][Full Text] [Related]
53. Event-related Potentials Improve the Efficiency of Cerebrospinal Fluid Biomarkers for Differential Diagnosis of Alzheimer's Disease. Babić Leko M; Krbot Skorić M; Klepac N; Borovečki F; Langer Horvat L; Vogrinc Ž; Sonicki Z; Hof PR; Šimić G Curr Alzheimer Res; 2018; 15(13):1244-1260. PubMed ID: 30207231 [TBL] [Abstract][Full Text] [Related]
54. Blood-based biomarkers in Alzheimer's disease: a mini-review. Padala SP; Newhouse PA Metab Brain Dis; 2023 Jan; 38(1):185-193. PubMed ID: 36342582 [TBL] [Abstract][Full Text] [Related]
55. Diagnostic Accuracy of Cerebrospinal Fluid Amyloid-β Isoforms for Early and Differential Dementia Diagnosis. Struyfs H; Van Broeck B; Timmers M; Fransen E; Sleegers K; Van Broeckhoven C; De Deyn PP; Streffer JR; Mercken M; Engelborghs S J Alzheimers Dis; 2015; 45(3):813-22. PubMed ID: 25633670 [TBL] [Abstract][Full Text] [Related]
56. Novel Ultrasensitive Detection Technologies for the Identification of Early and Minimally Invasive Alzheimer's Disease Blood Biomarkers. Álvarez-Sánchez L; Peña-Bautista C; Baquero M; Cháfer-Pericás C J Alzheimers Dis; 2022; 86(3):1337-1369. PubMed ID: 35213367 [TBL] [Abstract][Full Text] [Related]
57. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies. Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009 [TBL] [Abstract][Full Text] [Related]
58. Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study. Chiaravalloti A; Barbagallo G; Ricci M; Martorana A; Ursini F; Sannino P; Karalis G; Schillaci O Brain Res; 2018 Jan; 1678():116-122. PubMed ID: 29066367 [TBL] [Abstract][Full Text] [Related]